Eli Lilly & Co. (LLY) said its investigational long-lasting treatment for diabetes showed positive results in additional Phase III studies.
The latest two long-term studies of drug--dulaglutide for type 2 diabetes--showed Lilly's drug was more effective in reducing hemoglobin A1c--an indicator of blood sugar levels--in patients with type 2 diabetes compared with other diabetes treatments.
In October, the company reported dulaglutide showed positive results in lowering overall blood glucose levels in another series of Phase III studies.
Lilly and other drug makers have been racing to fill their product pipelinesto help compensate for the loss of patent exclusivity on former blockbuster drugs. Diabetes is one area where Lilly has been expanding, recently unveiling plans to add about 300 sales positions to the business that sells diabetes treatments, though it has been cutting back in other areas.
No comments:
Post a Comment